Study study type PathologyT1T0Patientssample sizesROB Results

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus paclitaxel
pembrolizumab alone
KEYNOTE-061 (all population), 2018
  NCT02370498
RCTmGC or mGEJC - L2 - all populationpembrolizumabpaclitaxelpatients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine296 / 296some concern
inconclusive
  • statistically significant 49 % increase in progression or deaths (PFS)

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive

versus paclitaxel
pembrolizumab alone
KEYNOTE-061 (PDL1 CPS>1), 2018
  NCT02370498
RCTmGC or mGEJC - L2 - PDL1 positivepembrolizumabpaclitaxelpatients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine (PDL1 CPS>1 population)196 / 199some concern
inconclusive
  • inconclusive 18 % decrease in deaths (OS) (PE)
  • statistically significant 27 % increase in progression or deaths (PFS) (PE)